Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive December 1, 2006 Sarah Houlton	Global Report: Not So NICE A new manifesto by the Association of the British Pharmaceutical Industry is designed to improve drug access in the UK, where industry has worried for years about poor uptake of new medicines.
Pharmaceutical Executive December 1, 2011	UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity.
Chemistry World December 8, 2011 Maria Burke	Government Launches UK Life Sciences Strategy Prime minister David Cameron has announced a package of measures designed to boost the UK's life sciences industry.
Chemistry World March 17, 2014 Phillip Broadwith	UK to fast-track access to critical medicines Critically ill patients in the UK could receive new medicines before they are formally approved under a new scheme beginning in April.
Pharmaceutical Executive August 1, 2008 Sarah Houlton	Jumping the Gun The Association of the British Pharmaceutical Industry and the British government have come up with a solution for price regulation that isn't as bad as the industry had feared.
Pharmaceutical Executive September 1, 2011 Richard Barker	Innovating Around Innovation The former Director General of ABPI, proposes a new agenda on how to restore public confidence in the value behind science.
Pharmaceutical Executive October 1, 2014 Leela Barham	The Gate Keeper Dr. David Haslam, Chair of the UK's National Institute of Health and Care Excellence, discusses what the quantitative calculations of value mean to patient access in today's messy world of real-time medicine.
Chemistry World October 8, 2010 Sarah Houlton	U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness.
The Motley Fool September 8, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
Pharmaceutical Executive May 1, 2012	Value-Based Pricing: Too High a Price for UK Pharma? Changes to the system in the UK could finally put some real metrics behind the elusive concept of value but with payers clearly in the driver's seat, who needs clarity?
Chemistry World January 3, 2013 Sarah Houlton	2012 pharma industry roundup It may have been a relatively quiet year in terms of mergers and acquisitions, but the pharma industry nonetheless made plenty of headlines in 2012.
Pharmaceutical Executive June 1, 2007 Jill Wechsler	Washington Report: Shop and Compare Insurers and payers believe that more comparative information on medical treatments will save money and improve care, but such analysis may be costly to pharma.
Chemistry World March 4, 2013 Andy Extance	UK considers patent rule change for trials The UK has announced plans to amend aspects of its patent law that may be encouraging pharma companies to run their clinical trials in other countries.
Chemistry World October 17, 2012 Maria Burke	GSK pledge on trials transparency GlaxoSmithKline has announced a series of initiatives to make clinical trial data publically available that could set a precedent in an industry not known for its transparency.
Pharmaceutical Executive April 1, 2007 Sarah Houlton	Global Report: If It Ain't Broke Under the UK's pricing scheme, drug prices have dropped by 21% in 10 years. Is it really time for a change?
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
Chemistry World May 4, 2006 Katharine Sanderson	Cancer Charity Takes on Shelved Drugs Cancer Research UK, and its commercial arm, Cancer Research Technology have launched a clinical development partnership scheme to sweep up drug candidates that pharmaceuticals companies have deprioritized for not showing enough commercial promise.
Pharmaceutical Executive June 1, 2012 Jill Wechsler	Innovation and Collaboration A rash of "pro-innovative" approaches for testing and regulating medical products offer ways to speed more new products to market.
Pharmaceutical Executive July 3, 2007 Sarah Houlton	Global Report: Five-Year Survivor: European Edition The UK government's attitude seems to be that oncology treatments are hugely expensive -- and that too much of the National Health Service budget is vanishing into the pockets of drug companies. Will cancer networks fill the gap?
Chemistry World July 2010	Meeting Mr NICE guy Bibiana Campos-Seijo meets the chief executive of the National Institute for Health and Clinical Excellence, Sir Andrew Dillon
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
Investment Advisor December 2005 Greg B. Scott	Buying The Future Prudent investing in biotechnology can offer great returns for clients. It's also the wave of the future. Armed with a basic understanding of the dynamics of the industry and the valuation inflection points, intelligent investors can make significant returns.
Pharmaceutical Executive May 1, 2005 Sarah Houlton	Global Report: Iron Fist The United Kingdom is hardening its stance on pharma industry issues.
Chemistry World September 30, 2014	Transparency measures forced on pharma Previous misdemeanors are compelling the pharmaceutical industry to be more open with financial information and clinical data.
Chemistry World November 21, 2008 Pete Mitchell	UK drug price deal finalised The new deal is guaranteed to continue for five years - a great relief to the industry.
Pharmaceutical Executive March 1, 2012 Ron Cohen	FDA's Necessary Dose of Reality There's no fast-acting salve, but there are several steps that can be taken to streamline many of the procedures at FDA. And it begins with leadership.
Pharmaceutical Executive November 1, 2005 Sarah Houlton	Global Report: Drug Evaluation in the UK The availability of new medicines has been thrown into the limelight once more, with UK's National Institute for Health and Clinical Excellence being called upon to make dramatic improvements to the speed at which it carries out evaluations.
The Motley Fool August 9, 2010 Jim Mueller	3 Stocks to Play Biotech Three promising ideas for investing in this exciting area.
Pharmaceutical Executive December 1, 2010 Zhu Shen	China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda
Pharmaceutical Executive January 1, 2014 Jill Wechsler	Pharma Challenges for 2014 Pricing and personalized medicine are key themes shaping drug development and marketing
Pharmaceutical Executive January 1, 2013 William Looney	The Permanent Campaign Promoting the merits of private-sector drug innovation is no easy task; just ask the UK's Office of Health Economics, with a record 50 years of engagement around the hard policy questions that ultimately drive success in the pharmaceutical marketplace.
Chemistry World August 23, 2012 Simon Campbell	Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth.
Pharmaceutical Executive August 1, 2012 Leela Barham	The Queen's English Defining the language of value based pricing in the United Kingdom and ultimately the world.
Pharmaceutical Executive November 1, 2008 Jill Wechsler	Resolving Conflicting Interests The Physician Payment Sunshine Act would require pharmaceutical and medical device companies to disclose payments of more than $500 to doctors.
Pharmaceutical Executive May 1, 2011 Julian Upton	UK Stakeholders Have Their Say on Value-Based Pricing The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance.
The Motley Fool June 21, 2004 Brian Gorman	Clinical Trials Controversy The American Medical Association wants more transparency in clinical trials, a proposal that may leave drug companies and investors with mixed feelings.
Chemistry World May 15, 2009 Katrina Megget	Tripping over red tape The UK may be moving a step closer to allowing the use of a cannabis-based drug to treat the symptoms of multiple sclerosis
Pharmaceutical Executive November 1, 2013 Jill Wechsler	Transparency Troubles for Pharma High prices, murky financial relations, and a reluctance to disclose clinical data undermine public trust in industry and the research enterprise.
Pharmaceutical Executive October 1, 2008 Sarah Houlton	Open For Debate Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems.
InternetNews July 27, 2010	FDA, FCC Push For Wireless Health Technology The government agencies are teaming up to use the latest and greatest wireless technology to improve care and reduce healthcare costs using electronic health records.
Chemistry World June 22, 2011 Sarah Houlton	US Approves Cancer Drugs Twice as Fast as Europe Cancer drugs are, on average, approved nearly twice as fast in the US than they are in Europe.
Chemistry World September 5, 2014 Emma Stoye	Servier to appear in adverts over lack of transparency European pharma group Servier Laboratories is to appear in adverts for breaching the Association of the British Pharma Industry code of practice by failing to publish clinical trial results.
Pharmaceutical Executive May 1, 2005	Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short.
Chemistry World May 27, 2015 Phillip Broadwith	Label laundry It's been an interesting month in the world of off-label pharmaceuticals.
Pharmaceutical Executive November 1, 2008 Sarah Houlton	Cash Flow Woes in EU In Europe, the wildly different attitudes toward healthcare across the different member states make for a complex pharmaceutical marketplace.
Chemistry World December 17, 2015 Sarah Houlton	Pills, prices and politics Pharmaceutical pricing has been a hot topic in 2015, with the drugs bill continuing to rise as costly new treatments reach the market.
Chemistry World December 15, 2009 Sarah Houlton	Pharma's year of merger mania Away from the corporate world, the big pharma story of 2009 was the emergence of a new health scare - swine flu.
Chemistry World September 7, 2015	Cancer Drugs Fund axes 23 treatments The Cancer Drugs Fund, which covers the cost of some cancer treatments that are not currently available on the National Health Service, has cut 23 treatments -- involving 16 drugs.
Pharmaceutical Executive January 21, 2014 Comer & Upton	Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday.
Pharmaceutical Executive September 1, 2013 Jill Wechsler	Biopharma Innovation in Trouble? Regulators, sponsors seek more productive research strategies.